Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Cardiologist Dr. Mikhail Kosiborod is clinical researcher at Saint Luke’s Mid America Heart Institute, and professor of medicine at the University of Missouri-Kansas City. He is a world-leading expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality of care and outcomes in patients with cardiovascular disease. On May 13, 2016, Dr. Kosiborod delivered this keynote address at the Ted Rogers Centre for Heart Research 1st Scientific Symposium.
The prevalence of both heart failure and type 2 diabetes are reaching epidemic proportions across the globe. Diabetes is a major risk factor for developing heart failure (both HFrEF and HFpEF), and more than 40% of patients with established heart failure have type 2 diabetes — a figure likely to rise in light of projected marked increases in the prevalence of type 2 diabetes.
Once patients with type 2 diabetes develop incident heart failure, their outcomes are extraordinarily poor. Thus, better understanding of the epidemiology, mechanisms and management of heart failure in these patients is of paramount importance. The objective of this presentation will be to review these key topics, with specific focus on the novel management strategies that have a promise to improve outcomes in this vulnerable patient group with concomitant diabetes and heart failure.
